Ancillary Studies to the Ad Neuroimaging Initiative (R21) | Apply Online

Opportunity Summary:

The NIH grant opportunity "Ancillary Studies to the AD Neuroimaging Initiative (R21)" (Funding Opportunity Number PA-06-241) supports short, exploratory research projects that add value to the Alzheimer s Disease Neuroimaging Initiative (ADNI). ADNI is a large, multi-site, longitudinal study that follows people across three groups: normal cognitive aging, mild cognitive impairment (MCI), and early Alzheimer s disease (AD). The core purpose of this FOA is to encourage outside investigators to leverage ADNI s infrastructure, samples, and data to generate new biomarker findings, develop improved analytic methods, or extend ADNI-like approaches into complementary studies that still align with the ADNI framework.

A central feature of ADNI is its systematic collection and long-term storage of biological specimens over time. ADNI gathers serial blood, cerebrospinal fluid (CSF), and urine samples from participants in each diagnostic group, and these samples are processed and banked so they can be analyzed for biological signals tied to disease presence and progression. The FOA emphasizes biomarkers that can be linked to ADNI s rich clinical and research dataset, including clinical outcomes, neuropsychological testing, and neuroimaging measures. Example biomarker domains explicitly highlighted include genomic, proteomic, and metabolomic markers, reflecting a broad interest in molecular indicators that might track disease risk, stage, or rate of decline. The announcement also notes that immortalized cell lines will be established, which creates additional opportunities for mechanistic or molecular follow-up work that benefits from renewable biological material.

Projects proposed under this FOA are meant to be "ancillary" to ADNI, meaning they complement and extend what ADNI already does rather than duplicating the parent study. The opportunity is deliberately broad in what it will consider as long as the work clearly enhances the scientific return of ADNI. Applications may focus on proposing and measuring new candidate biomarkers using the stored specimens, especially markers that could help predict progression from MCI to AD, distinguish normal aging from early disease, or serve as surrogate indicators of underlying pathology. The FOA also encourages applicants to contribute new approaches for analyzing existing ADNI data, such as improved image processing pipelines, novel quantitative imaging measures, advanced statistical modeling strategies, or other computational methods that increase the interpretability, sensitivity, or reproducibility of ADNI findings. In addition, investigators may propose parallel neuroimaging studies that enroll a different sample but use a subset of ADNI protocol measures, allowing comparisons or replication while still staying methodologically connected to ADNI. Autopsy studies are also within scope, reflecting interest in tying in vivo imaging and biomarker measures to definitive neuropathological outcomes when feasible.

This is an R21 mechanism, which generally signals early-stage or high-impact exploratory work rather than large, long-term confirmatory studies. The listed award ceiling is $200,000, positioning the program to fund smaller projects that can generate preliminary evidence, validate promising markers, or demonstrate the usefulness of new analytic tools. The FOA indicates there is no cost sharing or matching requirement, reducing financial barriers for applicants.

Eligibility is expansive and includes many types of U.S. organizations and government entities, such as state and local governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, and a wide range of nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities). For-profit organizations (other than small businesses) are also listed as eligible, and the announcement explicitly states that foreign institutions may apply. Eligible agencies of the Federal Government may apply as well. This broad eligibility is consistent with the FOA s goal of drawing in diverse expertise, including academic, clinical, computational, and industry-adjacent teams that can contribute novel assays, platforms, or methods relevant to ADNI resources.

Administratively, the opportunity falls under the NIH, is categorized as discretionary grant funding, and is associated with health-related funding activity categories. It lists CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health) and 93.866 (Aging Research), signaling both a technology/innovation angle and a direct alignment with aging and Alzheimer s disease research. The FOA was posted March 17, 2006, and uses multiple receipt dates (applicants are directed to the full announcement for the specific schedule). The archive date shown is June 1, 2009, indicating the original FOA is no longer active as a current solicitation, though it remains informative as a description of the program NIH was running at the time.

In practical terms, a competitive application under this FOA would typically make a clear case that it can use ADNI specimens and/or data, or generate ADNI-compatible data, to answer a focused question about disease mechanisms, diagnosis, prognosis, or progression. Strong proposals would also explain how the work will connect biomarker or analytic outputs back to ADNI s clinical, cognitive, and imaging endpoints, since the program is built around integrating biology with longitudinal phenotyping. The full announcement is linked at http://grants.nih.gov/grants/guide/pa-files/PA-06-241.html, and NIH provides a contact email (FBOWebmaster@OD.NIH.GOV) for technical issues accessing the posting.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Aging Musculoskeletal and Skin Extracellular Matrix (R21)

Previous opportunity: Ancillary Studies to the AD Neuroimaging Initiative (R03)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 06 241

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 06 241) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 241", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.